Add-on durvalumab (Imfinzi) reduced the number of early high-risk disease recurrences within the first year in patients with ...

In the durvalumab-plus-tremelimumab arm, more patients went on to receive subsequent treatment, 66%, in particular, systemic therapy, 47%, of whom most received platinum doublet therapy, 42% thus far.

Findings from the primary analysis of the phase 3b PATAPSCO study showed that adding durvalumab (Imfinzi) to BCG induction ...

A regulatory decision on the application is expected during the fourth quarter of 2024. The Food and Drug Administration (FDA) has granted Priority Review to the supplemental Biologics License ...

The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...

Interim findings from the DUO-O trial could signal new options for women diagnosed with ovarian cancer at later stages who do not have a BRCA mutation. Patients newly diagnosed with advanced ovarian ...

Durvalumab administered after chemoradiotherapy was effective and was associated with prolonged overall survival and progression‑free survival in patients with unresectable, stage III non-small cell ...

Durvalumab received FDA breakthrough therapy designation for PD-L1—positive metastatic urothelial bladder cancer, aiming to expedite its development. The phase 3 DANUBE study compares durvalumab ...

Durvalumab therapy after chemoradiotherapy significantly improves overall and progression-free survival in patients with limited-stage small cell lung cancer (SCLC). The median overall survival was 55 ...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Updated results from the BEGONIA phase 1b/2 trial for the cohort of patients treated with datopotamab deruxtecan (Dato-DXd) plus durvalumab (Arm 7) showed ...

High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) ...

The evaluation committee considered evidence submitted by AstraZeneca, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for ...